Nurix Therapeutics price target raised to $34 from $32 at Truist
Truist analyst Gregory Renza raised the firm's price target on Nurix Therapeutics to $34 from $32 and keeps a Buy rating on the shares after its Q2 results. The company's earnings and the firm's follow-up call with the management were focused on the recent Roche (RHHBY) partnership, which further broadens the path to value creation for Nurix, the analyst tells investors in a research note. Nurix management also highlighted greater flexibility to explore bexdeg combos in earlier lines besides the ongoing pivotal CLL-201 and the planned phase 3 CLL-306, the firm added.
Truist analyst Gregory Renza raised the firm's price target on Nurix Therapeutics to $34 from $32 and keeps a Buy rating on the shares after its Q2 results.
The company's earnings and the firm's follow-up call with the management were focused on the recent Roche (RHHBY) partnership, which further broadens the path to value creation for Nurix, the analyst tells investors in a research note.
Nurix management also highlighted greater flexibility to explore bexdeg combos in earlier lines besides the ongoing pivotal CLL-201 and the planned phase 3 CLL-306, the firm added.